MET and lung carcinoma: While in the non-exposed lung cancer cohort no tumour had an alteration in the MET gene, five patients (25%) of the Rn-exposed cohort showed alterations in this gene, whereof four tumours showed a substitution and missense mutation (for detail see Table S1) and in one tumour there was an amplification of MET, although classified as low level.